Kyeong Jin Kim, Eyun Song, Mijin Kim, Hyemi Kwon, Eu Jeong Ku, Hyun Woo Kwon, Jee Hee Yoon, Eun Kyung Lee, Won Woo Lee, Young Joo Park, Dong-Jun Lim, Sun Wook Kim, Ho-Cheol Kang, Jae Hoon Chung, Tae Yong Kim, Sin Gon Kim, Dong Gyu Na, Jee Soo Kim
Endocrinol Metab. 2025;40(3):342-356. Published online June 24, 2025
Hyperthyroidism is a condition marked by excessive thyroid hormone production, most commonly due to Graves’ disease. Treatment options include antithyroid drugs (ATD), radioactive iodine (RAI) therapy, and thyroidectomy. To develop standardized clinical recommendations for RAI therapy with a focus on safety, efficacy, and monitoring, the Korean Thyroid Association formed a task force to create evidence-based guidelines. Six key clinical questions were identified through expert consensus, and a systematic literature review from 2013 to 2022 was conducted. Clinical indications for RAI therapy were categorized into three groups: strongly recommended, may be considered, and not recommended. A fixed dose of 10 to 15 mCi is recommended. Although a strict low-iodine diet is unnecessary, iodine-rich foods should be avoided for at least 1 week before treatment. ATD should be stopped 3 to 7 days before RAI and may be resumed in select cases. Prophylactic glucocorticoids are recommended for patients with mildly active thyroid eye disease and may be considered for others at risk. Thyroid function should be monitored at 4–6 weeks post-treatment, every 2–3 months until stabilized, and then every 6–12 months. These guidelines highlight recent advances and underscore the importance of individualized treatment based on clinical features, comorbidities, and patient preferences in Korea.
Citations
Citations to this article as recorded by
Outcome of MRI-Guided Single-Dose Iodine-131 for Graves’ Hyperthyroidism with Large Goiter Shangcheng Yan, Xiansheng Chen, Bing Yan, Xin Li, Zhen Cao, Pan Zhang, Yajun Wang, Wenmei Guo, Ziwen Liu Annals of Nuclear Medicine.2026;[Epub] CrossRef
Background Heart rate (HR) monitored by a wearable device (WD) has demonstrated its clinical feasibility for thyrotoxicosis subjects. However, the association of HR monitored by wearables with hypothyroidism has not been examined. We assessed the association between serum thyroid hormone concentration and three WD-HR parameters in hypothyroid subjects.
Methods Forty-four subjects scheduled for radioactive iodine therapy (RAI Tx) after thyroid cancer surgery were included. Thirty subjects were prepared for RAI Tx by thyroid hormone withdrawal (hypothyroidism group) and 14 subjects by recombinant human thyrotropin (control group). Three WD-HR parameters were calculated from the HR data collected during rest, during sleep, and from 2:00 AM to 6:00 AM, respectively. We analyzed the changes in conventionally measured resting HR (On-site rHR) and WDHR parameters relative to thyroid hormone levels.
Results Serum free thyroxine (T4) levels, On-site rHR, and WD-HR parameters were lower in the hypothyroid group than in the control group at the time of RAI Tx. WD-HR parameters also reflected minute changes in free T4 levels. A decrease in On-site rHR and WD-HR parameters by one standard deviation (On-site rHR, approximately 12 bpm; WD-HR parameters, approximately 8 bpm) was associated with a 0.2 ng/dL decrease in free T4 levels (P<0.01) and a 2-fold increase of the odds ratio of hypothyroidism (P<0.01). WD-HR parameters displayed a better goodness-of-fit measure (lower quasi-information criterion value) than On-site rHR in predicting the hypothyroidism.
Conclusion This study identified WD-HR parameters as informative and easy-to-measure biomarkers to predict hypothyroidism.
Citations
Citations to this article as recorded by
Cost-effectiveness Analysis Comparing Conventional and Digital Software Supported Management for Hypothyroidism Jung Hyun Kim, Jaeyong Shin, Man S Kim, Jae Hoon Moon The Journal of Clinical Endocrinology & Metabolism.2025; 110(6): 1596. CrossRef
An explainable non-invasive hybrid machine learning framework for accurate prediction of thyroid-stimulating hormone levels Areej Mohammed, Hussam Alshraideh, Munir Abu-Helalah, Abdulrahim Shamayleh Computers in Biology and Medicine.2025; 189: 109974. CrossRef
Application progress of artificial intelligence in managing thyroid disease Qing Lu, Yu Wu, Jing Chang, Li Zhang, Qing Lv, Hui Sun Frontiers in Endocrinology.2025;[Epub] CrossRef
A Digital Software Support Platform for Hyperthyroidism Management in South Korea: Markov Simulation Model-Based Cost-Effectiveness Analysis Jung Hyun Kim, Jaeyong Shin, Man S Kim, Jae Hoon Moon JMIR mHealth and uHealth.2025; 13: e56738. CrossRef
Application of wearables for remote monitoring of oncology patients: A scoping review Katharina Cloß, Marlo Verket, Dirk Müller-Wieland, Nikolaus Marx, Katharina Schuett, Edgar Jost, Martina Crysandt, Fabian Beier, Tim H Brümmendorf, Guido Kobbe, Julia Brandts, Malte Jacobsen DIGITAL HEALTH.2024;[Epub] CrossRef
Association between resting heart rate and low natural killer cell activity: a cross-sectional study Hyoju Oh, A-Ra Cho, Joo-Hwan Jeon, Eunkyung Suh, Junhyung Moon, Baek Hwan Cho, Yun-Kyong Lee Frontiers in Immunology.2024;[Epub] CrossRef
Thyroid hormone action during GABAergic neuron maturation: The quest for mechanisms Sabine Richard, Juan Ren, Frédéric Flamant Frontiers in Endocrinology.2023;[Epub] CrossRef
A machine learning-assisted system to predict thyrotoxicosis using patients’ heart rate monitoring data: a retrospective cohort study Kyubo Shin, Jongchan Kim, Jaemin Park, Tae Jung Oh, Sung Hye Kong, Chang Ho Ahn, Joon Ho Moon, Min Joo Kim, Jae Hoon Moon Scientific Reports.2023;[Epub] CrossRef